SCHEMBL2299710

SCHEMBL2299710

COCC(NC(=O)c1cc(-c2cccc(Nc3nc4ccc(F)cc4s3)c2)no1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 6/20 0.46
DGAT1 O75907 2/20 0.46
MAPT P10636 6/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
GAA P10253 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
TNF P01375 1/20 0.42
NR2F2 P24468 1/20 0.42
MCL1 Q07820 1/20 0.42
KLF5 Q13887 1/20 0.42
NOD1 Q9Y239 1/20 0.42
ALDH1A1 P00352 3/20 0.40
ALPL P05186 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299698 1.00 CSGALNACT1 (0.46) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2297520 0.94 DGAT1 (0.43) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2297526 0.94 DGAT1 (0.43) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2297260 0.92 RAB9A (0.43) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2297248 0.92 RAB9A (0.43) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2296831 0.92 CSGALNACT1 (0.53) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2296847 0.92 CSGALNACT1 (0.53) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2301923 0.91 DGAT1 (0.42) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2301905 0.91 DGAT1 (0.42) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1
SCHEMBL2301911 0.91 DGAT1 (0.42) CSGALNACT1DGAT1MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT CSGALNACT1 455/4885DGAT1 1/4885MAPT 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.